Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Influence Of Familial Pancreatic Cancer On Postoperative Outcome In Pancreatic Cancer: Relevance To Adjuvant Chemotherapy

K. Tezuka, Y. Okamura, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, R. Ashida, K. Ohgi, K. Uesaka
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Familial pancreatic cancer (FPC) is defined as a family in which at least two first-degree relatives have pancreatic cancer (PC). The prognostic significance of PC in an FPC family after surgery is not fully understood. This was a retrospective study of 427 patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma between January 2008 and December 2016. PC patients who also had at least one first-degree relative with PC were defined as FPC patients. The associations between recurrence and clinicopathological characteristics were analyzed for both FPC and non-FPC patients. FPC patients accounted for 31 of the 427 (7.3%) patients. Recurrence occurred in 72.1% of the total cohort and in 87.1% of the 31 FPC patients. Multivariate analysis showed that being an FPC patient was an independent predictor for relapse-free survival (RFS) (hazard ratio [HR] 1.52, P = 0.038). Although univariate analysis revealed that being an FPC patient was significantly associated with poorer overall survival (OS) (P < 0.001), multivariate analysis showed that being an FPC patient was not an independent predictor for OS (P = 0.164). Dichotomization of the 427 patients into those who received (n = 317: 17 FPC and 300 non-FPC patients) and did not receive (n = 110: 14 FPC and 96 non-FPC patients) adjuvant chemotherapy revealed that being an FPC patient was an independent predictor for RFS (HR 2.50, P < 0.001) and OS (HR 2.30, P = 0.003) only for patients who received adjuvant chemotherapy. This study has shown that being an FPC patient is a significant prognostic indicator for PC patients who undergo resection and receive adjuvant chemotherapy.
This paper references
10.1001/jama.2013.279201
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
H. Oettle (2013)
10.1007/s00534-013-0611-5
Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012
K. Wada (2013)
SEER Cancer Statistics Review, 1975-2003
L. Ries (2006)
10.1245/s10434-015-4823-6
Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis
M. Mavros (2015)
10.1007/s11605-011-1417-x
Patterns of Pancreatic Resection Differ Between Patients with Familial and Sporadic Pancreatic Cancer
J. Barton (2011)
10.1007/s11605-009-0923-6
Assessment of “Gene–Environment” Interaction in Cases of Familial and Sporadic Pancreatic Cancer
T. Yeo (2009)
10.1159/000134272
Survival in Familial Pancreatic Cancer
J. Ji (2008)
10.1136/gutjnl-2019-319352
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium
M. Goggins (2019)
10.1056/NEJMoa1809775
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy (2018)
10.1038/nrclinonc.2013.66
Advanced-stage pancreatic cancer: therapy options
J. Werner (2013)
10.1016/j.surg.2013.04.015
Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer.
T. Sugiura (2013)
10.14740/wjon1166
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla (2019)
10.1002/cncr.28863
Clinical and pathologic features of familial pancreatic cancer
Jeremy L. Humphris (2014)
10.3390/ijms20030561
Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer
A. Ohmoto (2019)
10.18632/oncotarget.12490
Germline mutations in Japanese familial pancreatic cancer patients
Erina Takai (2016)
10.1007/s10689-014-9755-y
Familial and sporadic pancreatic cancer share the same molecular pathogenesis
Alexis L. Norris (2014)
10.1038/ajg.2014.435
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
S. Syngal (2015)
10.1245/s10434-017-6324-2
Microscopic Venous Invasion in Pancreatic Cancer
M. Yamada (2017)
10.1016/j.jamcollsurg.2017.12.021
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
A. Blair (2018)
10.1053/j.seminoncol.2018.12.002
Neoadjuvant Treatment for Pancreatic Cancer.
Alexander G Raufi (2019)
10.1016/j.pan.2015.04.003
A histomorphologic comparison of familial and sporadic pancreatic cancers.
A. Singhi (2015)
10.1093/annonc/mdn527
Age of onset in familial cancer.
A. Brandt (2008)
10.1136/gut.2005.065045
Anticipation in familial pancreatic cancer
C. McFaul (2006)
10.1002/cncr.20700
Risk factors associated with earlier age of onset in familial pancreatic carcinoma
T. James (2004)
International Union Against Cancer. TNM classification of Malignant Tumours
JD Brierley (2017)
10.1002/ijc.20210
Prevalence of familial pancreatic cancer in Germany
D. Bartsch (2004)
10.1002/ijc.31937
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay (2019)
Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kickoff meeting at International Symposium on Pancreas
K Wada (2012)
10.7326/0003-4819-98-1-111_2
Familial pancreatic cancer.
M. Grajower (1983)
10.1158/0008-5472.CAN-03-3823
Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds
A. Klein (2004)
10.1007/s10689-019-00125-9
Progress report: familial pancreatic cancer
I. Mintziras (2019)
SEER data submission, posted to the SEER web site
M D Bethesda
10.1038/s41416-019-0582-7
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Max M Wattenberg (2019)
10.1016/S0140-6736(16)30583-9
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
K. Uesaka (2016)
10.18632/oncotarget.24865
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
T. Kondo (2018)
10.1093/jjco/hyaa018
Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
F. Motoi (2020)
10.1158/2159-8290.CD-15-0402
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.
N. Roberts (2016)



Semantic Scholar Logo Some data provided by SemanticScholar